All In Biotech

Drug Trial Radar · NCT05535946

ABTECT - Maintenance

A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,116 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,116

Actual

Start

Jan 16, 2023

Primary completion

Apr 28, 2026

Study completion May 2030

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

Conditions

  • Ulcerative Colitis

Interventions

  • ABX464Drug

    Administered once daily, preferably in the morning, with food

  • PlaceboDrug

    Administered once daily, preferably in the morning, with food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of subjects in clinical remission at Week 44Time frame: Week 44
  2. Number and percentage of all treatment-emergent adverse events (TEAEs)Time frame: Week 44
  3. Number and percentage of all serious adverse events (SAEs)Time frame: Week 44
  4. Number and percentage of all causally related TEAEs/SAEsTime frame: Week 44

Locations

413 sites in 34 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • Research Solutions of Arizona, PC

    Litchfield Park, Arizona

  • GI Alliance

    Sun City, Arizona

  • University of Arizona

    Tucson, Arizona

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Citrus Valley Gastroenterology

    Covina, California

  • University of California (San Diego)

    La Jolla, California

  • United Medical Doctors

    Murrieta, California

  • California Medical Research Associates Inc.

    Northridge, California

  • Clinnova Research Solutions

    Orange, California

  • Clinical Applications Laboratories

    San Diego, California

  • Kaiser Foundation Research Institute, a Division of Kaiser Permanente Hospitals

    Aurora, Colorado

  • Danbury Hospital

    Danbury, Connecticut

  • West Central Gastroenterology d/b/a Gastro Florida

    Clearwater, Florida

  • Nature Coast Clinical Research, LLC

    Inverness, Florida

  • Auzmer Research

    Lakeland, Florida

  • Infinite Clinical Research Inc

    Miami, Florida

  • Research Associates of South Florida, LLC

    Miami, Florida

  • University of Miami

    Miami, Florida

  • MedOne Clinical Research LLC

    Miami, Florida

  • Nicklaus Children's Hospital

    Miami, Florida

  • Medical Professional Clinical Research Center

    Miami, Florida

  • Wellness Clinical Research

    Miami Lakes, Florida

  • Ocala GI Research

    Ocala, Florida

  • Arnold Palmer Hospital For Children

    Orlando, Florida

  • Advanced Research Institute, Inc.

    Orlando, Florida

  • GCP Clinical Research, LLC

    Tampa, Florida

  • Guardian Angel Research Center

    Tampa, Florida

  • Alliance Clinical Research

    Tampa, Florida

  • Atlanta Center for Gastroenterology, P.C.

    Decatur, Georgia

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • GI Alliance

    Gurnee, Illinois

  • Iowa Digestive Disease Center

    Clive, Iowa

  • The University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • Lucida Clinical Trials LLC

    New Bedford, Massachusetts

  • Henry Ford Hospital

    Sterling Heights, Michigan

Showing 40 of 413 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.